Nektar Therapeutics buy TD Cowen
Start price
09.11.23
/
50%
€0.47
Target price
09.11.24
-
Performance (%)
209.06%
Price
03.05.24
€1.46
Summary
This prediction is currently active. With a performance of 209.06% the BUY prediction by TD_Cowen is a big success. This prediction currently runs until 09.11.24. The prediction end date can be changed by TD_Cowen at any time. TD_Cowen has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | 19.121% | 19.121% |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by TD_Cowen for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for NKTR provided by MarketBeat